Development and qualification of clinical grade decellularized and cryopreserved human esophagi.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
25 10 2023
Historique:
received: 30 05 2023
accepted: 21 10 2023
medline: 27 10 2023
pubmed: 26 10 2023
entrez: 25 10 2023
Statut: epublish

Résumé

Tissue engineering is a promising alternative to current full thickness circumferential esophageal replacement methods. The aim of our study was to develop a clinical grade Decellularized Human Esophagus (DHE) for future clinical applications. After decontamination, human esophagi from deceased donors were placed in a bioreactor and decellularized with sodium dodecyl sulfate (SDS) and ethylendiaminetetraacetic acid (EDTA) for 3 days. The esophagi were then rinsed in sterile water and SDS was eliminated by filtration on an activated charcoal cartridge for 3 days. DNA was removed by a 3-hour incubation with DNase. A cryopreservation protocol was evaluated at the end of the process to create a DHE cryobank. The decellularization was efficient as no cells and nuclei were observed in the DHE. Sterility of the esophagi was obtained at the end of the process. The general structure of the DHE was preserved according to immunohistochemical and scanning electron microscopy images. SDS was efficiently removed, confirmed by a colorimetric dosage, lack of cytotoxicity on Balb/3T3 cells and mesenchymal stromal cell long term culture. Furthermore, DHE did not induce lymphocyte proliferation in-vitro. The cryopreservation protocol was safe and did not affect the tissue, preserving the biomechanical properties of the DHE. Our decellularization protocol allowed to develop the first clinical grade human decellularized and cryopreserved esophagus.

Identifiants

pubmed: 37880340
doi: 10.1038/s41598-023-45610-5
pii: 10.1038/s41598-023-45610-5
pmc: PMC10600094
doi:

Substances chimiques

Sodium Dodecyl Sulfate 368GB5141J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18283

Informations de copyright

© 2023. Springer Nature Limited.

Références

Expert Rev Med Devices. 2014 Mar;11(2):225-41
pubmed: 24387697
Sci Rep. 2015 Dec 03;5:17635
pubmed: 26631592
Anal Biochem. 1978 Nov;91(1):230-5
pubmed: 9762103
Cell Transplant. 2017 Dec;26(12):1831-1839
pubmed: 29390879
Surgery. 1983 Jan;93(1 Pt 1):70-7
pubmed: 6217567
Lancet. 2018 Mar 3;391(10123):883-910
pubmed: 28987452
Immunol Today. 1993 Oct;14(10):480-2
pubmed: 7506033
Biomaterials. 2018 Aug;175:1-18
pubmed: 29793088
Immunopharmacology. 1992 Sep-Oct;24(2):149-60
pubmed: 1473965
Glycobiology. 2003 Sep;13(9):647-53
pubmed: 12773478
Biochem J. 1968 Oct;109(5):825-30
pubmed: 4177067
J Intensive Care Med. 2010 May-Jun;25(3):139-48
pubmed: 20444738
Biomaterials. 2011 Apr;32(12):3233-43
pubmed: 21296410
Curr Top Dev Biol. 2018;130:1-37
pubmed: 29853174
J Crit Care. 2011 Apr;26(2):225.e1-10
pubmed: 20951541
Nat Commun. 2018 Oct 16;9(1):4286
pubmed: 30327457
Arthritis Res Ther. 2020 Dec 7;22(1):283
pubmed: 33287871
Bioengineering (Basel). 2018 Dec 24;6(1):
pubmed: 30586900
Semin Cell Dev Biol. 2002 Oct;13(5):377-83
pubmed: 12324220
Tissue Eng. 2006 Feb;12(2):319-30
pubmed: 16548690
Ann N Y Acad Sci. 2018 Dec;1434(1):156-163
pubmed: 30088660
Am J Transplant. 2018 Aug;18(8):1857-1864
pubmed: 29513380
Tissue Eng Part A. 2011 Oct;17(19-20):2435-43
pubmed: 21563860
PLoS One. 2017 Jun 9;12(6):e0179341
pubmed: 28599006
J Biol Chem. 2012 Mar 30;287(14):11363-73
pubmed: 22298772
Surgery. 2022 Feb;171(2):384-392
pubmed: 34392978
J Res Natl Inst Stand Technol. 2013 Apr 11;118:151-67
pubmed: 26401428
J Vasc Surg. 2021 Feb;73(2):626-634
pubmed: 33485491
Biomed Rep. 2015 Sep;3(5):617-620
pubmed: 26405534
J Immunol Methods. 2002 Jun 1;264(1-2):37-43
pubmed: 12191507
Clin Infect Dis. 2016 Feb 15;62(4):e1-50
pubmed: 26679628
Artif Organs. 2010 Mar;34(3):206-10
pubmed: 20447045
Biores Open Access. 2020 Feb 21;9(1):22-36
pubmed: 32117597
Anal Biochem. 1988 Jul;172(1):259-63
pubmed: 3189769
Therap Adv Gastroenterol. 2020 May 26;13:1756284820923220
pubmed: 32523626
Cells. 2022 Sep 20;11(19):
pubmed: 36230907
Xenotransplantation. 2015 Mar-Apr;22(2):95-101
pubmed: 25641488
Tissue Eng Part A. 2019 Nov;25(21-22):1478-1492
pubmed: 30799779
Surgery. 2010 Jul;148(1):39-47
pubmed: 20117812
J Thorac Cardiovasc Surg. 2004 Feb;127(2):399-405
pubmed: 14762347
J Tissue Eng Regen Med. 2019 Dec;13(12):2191-2203
pubmed: 31670903
J Chir (Paris). 2009 Jun;146(3):240-9
pubmed: 19640531

Auteurs

William Godefroy (W)

Service de Chirurgie Viscérale, Cancérologique et Endocrinienne, Hôpital Saint-Louis - Université Paris Cité, Paris, France. william.godefroy@aphp.fr.
Unité de Thérapie Cellulaire, Hôpital Saint-Louis, AP-HP, Paris, France. william.godefroy@aphp.fr.
CIC de Biothérapies CBT 501, Paris, France. william.godefroy@aphp.fr.
Human Immunology, Pathophysiology, Immunotherapy / HIPI / INSERM UMR976, Laboratoire de Biotechnologies de Cellules Souches, Université Paris Cité, 75010, Paris, France. william.godefroy@aphp.fr.

Lionel Faivre (L)

Unité de Thérapie Cellulaire, Hôpital Saint-Louis, AP-HP, Paris, France.
CIC de Biothérapies CBT 501, Paris, France.
Human Immunology, Pathophysiology, Immunotherapy / HIPI / INSERM UMR976, Laboratoire de Biotechnologies de Cellules Souches, Université Paris Cité, 75010, Paris, France.

Caroline Sansac (C)

Banque de Tissus Humains, Hôpital St-Louis, AP-HP, Paris, France.

Briac Thierry (B)

Human Immunology, Pathophysiology, Immunotherapy / HIPI / INSERM UMR976, Laboratoire de Biotechnologies de Cellules Souches, Université Paris Cité, 75010, Paris, France.
Service d'ORL Pédiatrique, AP-HP, Hôpital Universitaire Necker, 75015, Paris, France.

Jean-Marc Allain (JM)

LMS, CNRS, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France.
Inria, Paris, France.

Patrick Bruneval (P)

Service d'Anatomie Pathologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.

Rémy Agniel (R)

Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Matériaux, I-MAT (FD4122), CY Cergy Paris Université, Cergy-Pontoise, France.

Sabrina Kellouche (S)

Equipe de Recherche sur les Relations Matrice Extracellulaire-Cellules, ERRMECe (EA1391), Institut des Matériaux, I-MAT (FD4122), CY Cergy Paris Université, Cergy-Pontoise, France.

Olivier Monasson (O)

CNRS, BioCIS, CY Cergy Paris Université, 95000, Cergy Pontoise, France.
CNRS, BioCIS, Université Paris-Saclay, 92290, Châtenay-Malabry, France.

Elisa Peroni (E)

CNRS, BioCIS, CY Cergy Paris Université, 95000, Cergy Pontoise, France.
CNRS, BioCIS, Université Paris-Saclay, 92290, Châtenay-Malabry, France.

Mohamed Jarraya (M)

Banque de Tissus Humains, Hôpital St-Louis, AP-HP, Paris, France.

Niclas Setterblad (N)

UMS Saint-Louis US53 / UAR2030, Institut de Recherche Saint-Louis Plateforme Technologique Centre, Université Paris Cité - Inserm - CNRS, Paris, France.

Massymissa Braik (M)

Unité de Thérapie Cellulaire, Hôpital Saint-Louis, AP-HP, Paris, France.

Benjamin Even (B)

Laboratoire Gly-CRRET, Université Paris Est Créteil, Université Paris Est, EA 4397 ERL CNRS 9215, Créteil, France.

Sophie Cheverry (S)

Laboratoire Gly-CRRET, Université Paris Est Créteil, Université Paris Est, EA 4397 ERL CNRS 9215, Créteil, France.

Thomas Domet (T)

Unité de Thérapie Cellulaire, Hôpital Saint-Louis, AP-HP, Paris, France.
CIC de Biothérapies CBT 501, Paris, France.

Patricia Albanese (P)

Laboratoire Gly-CRRET, Université Paris Est Créteil, Université Paris Est, EA 4397 ERL CNRS 9215, Créteil, France.

Jérôme Larghero (J)

Unité de Thérapie Cellulaire, Hôpital Saint-Louis, AP-HP, Paris, France.
CIC de Biothérapies CBT 501, Paris, France.
Human Immunology, Pathophysiology, Immunotherapy / HIPI / INSERM UMR976, Laboratoire de Biotechnologies de Cellules Souches, Université Paris Cité, 75010, Paris, France.
Centre MEARY de Thérapie Cellulaire Et Génique, AP-HP, Hôpital Saint-Louis, 75010, Paris, France.

Pierre Cattan (P)

Service de Chirurgie Viscérale, Cancérologique et Endocrinienne, Hôpital Saint-Louis - Université Paris Cité, Paris, France.
Unité de Thérapie Cellulaire, Hôpital Saint-Louis, AP-HP, Paris, France.
CIC de Biothérapies CBT 501, Paris, France.
Human Immunology, Pathophysiology, Immunotherapy / HIPI / INSERM UMR976, Laboratoire de Biotechnologies de Cellules Souches, Université Paris Cité, 75010, Paris, France.

Lousineh Arakelian (L)

Unité de Thérapie Cellulaire, Hôpital Saint-Louis, AP-HP, Paris, France. lousineh.arakelian@aphp.fr.
CIC de Biothérapies CBT 501, Paris, France. lousineh.arakelian@aphp.fr.
Human Immunology, Pathophysiology, Immunotherapy / HIPI / INSERM UMR976, Laboratoire de Biotechnologies de Cellules Souches, Université Paris Cité, 75010, Paris, France. lousineh.arakelian@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH